Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

Background Patients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease have limited treatment options. Previously, we showed targeting programmed death-ligand 1 (PD-L1) with durvalumab (durva) and radiation therapy (RT) combination was safe in BC. We now report result...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Hong Zheng, Junjia Zhu, Monika Joshi, Mark Stein, Alexander Sankin, Deepak Kilari, Yousef Zakharia, Joseph Drabick, Ralph Hauke, Hamid Emamekhoo, Todd Schell, Leonard Tuanquin, Vonn Walter, Matthew Kaag, Jiangang Liao, Sheldon L Holder, Suzzane Merrill, Joshua Warrick, Benjamin Gartrel, David J Degraff
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-02-01
Online Access:	https://jitc.bmj.com/content/11/2/e006551.full